Business Context and Reporting Period
This Form 6-K filing by Ascendis Pharma A/S covers the month of December 2025, with a report date of December 10, 2025. The filing primarily addresses a corporate action involving the grant of employee warrants and an amendment to the Company's Articles of Association.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity compensation terms rather than financial performance results.
Material Changes
- Warrant Grant: On December 9, 2025, the Board of Directors granted 27,820 warrants to certain employees.
- Exercise Price: The exercise price is set at US $196.63 per share, based on the closing price of the American Depositary Shares (ADS) on the grant date.
- Vesting Schedule: 25% of the warrants vest on the one-year anniversary of the grant date. The remaining 75% vest monthly at a rate of 1/36th thereafter, subject to continued service.
- Remaining Pool: Following this grant, 1,725,233 warrants remain available for future grants under the Articles of Association.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, outlook, or specific risks. The only contingency noted is that vesting is subject to continued service and may accelerate upon the occurrence of certain exit events.
Investor Verification Checklist
- Verify the total number of outstanding warrants and the remaining pool size (1,725,233) in the updated Articles of Association.
- Confirm the impact of the 27,820 new warrants on potential future dilution.
- Review the specific "exit events" defined in the Articles of Association that could trigger accelerated vesting.
- Check subsequent filings for any financial results or updates not included in this specific 6-K.